Betta IPO Tells Tale Of Shifting Strategy By China Innovators
This article was originally published in PharmAsia News
As a national innovation darling, Betta Pharma is gearing up to a much-hyped public listing in China. Combing through its 300-plus page prospectus, however, unveils a different Betta striving to diversify amid looming competition and price pressure.
You may also be interested in...
In a bold move to expand into cancer treatment markets, Siemens Healthineers has agreed to a $16.4bn all-cash deal to acquire radiation therapy leader Varian.
Chi-Med has revised its commercial rights agreement in China for Elunate (fruquintinib) with Lilly to seize China’s rapid growth trajectory, CEO Christian Hogg tells Scrip.